Pharmaceuticals

Global Glycopeptide Antibiotics Market 2026–2030: Forecast Insights for Business Planning

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the glycopeptide antibiotics market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Glycopeptide Antibiotics Market?

The glycopeptide antibiotics market has experienced robust growth in recent years. It is projected to expand from $3.78 billion in 2025 to $4.13 billion in 2026, at a compound annual growth rate (CAGR) of 9.0%. Historically, this expansion can be attributed to an uptick in hospital-acquired infections, the broad adoption of vancomycin as standard therapy, a growing prevalence of gram-positive bacterial infections, the restricted availability of alternative antibiotics, and the expansion of inpatient healthcare infrastructure.

The glycopeptide antibiotics market size is anticipated to experience substantial growth in the upcoming years. It is forecast to expand to $5.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.3%. This expansion during the forecast period is primarily driven by the increasing prevalence of multidrug-resistant pathogens, the growing uptake of long-acting glycopeptides, the rising need for outpatient and home-based antibiotic therapies, continuous research and development into next-generation glycopeptides, and an increase in global healthcare expenditure. Significant trends for this period encompass a heightened reliance on glycopeptides for managing resistant infections, an expansion of the lipoglycopeptide antibiotics portfolio, increased utilization of intravenous glycopeptides in hospital settings, a greater focus on optimized dosing and therapeutic monitoring, and broader application in severe gram-positive infections.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp

What Drivers Are Supporting Technological Adoption In The Glycopeptide Antibiotics Market?

The glycopeptide antibiotic market is projected for growth in the coming years, driven by the increasing prevalence of gram-positive infections. These infections are caused by gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes. Glycopeptide antibiotics demonstrate efficacy against many gram-positive bacteria due to their distinct mechanism of action, which targets the formation of bacterial cell walls. For instance, in June 2023, the Group A Streptococcal Infections: Report on Seasonal Activity in England 2022–2023, published by the UK Health Security Agency, a UK-based government body responsible for public health and infectious-disease protection, showed a sharp rise in invasive Group A Streptococcus (iGAS) activity, with 509 laboratory-confirmed iGAS notifications reported by week 46 of 2023, including a weekly peak of 73 cases. This escalation highlights a growing infectious-disease burden, intensifying the demand for effective antimicrobial therapies across the healthcare system. Therefore, the expanding occurrence of gram-positive infections is a significant driver for the glycopeptide antibiotic market.

Which Segments Are Contributing To The Growth Of The Glycopeptide Antibiotics Market?

The glycopeptide antibiotics market covered in this report is segmented –

1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs

2) By Route of Administration: Oral, Parenteral, Other Routes

3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications

4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution

2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection

3) By Oritavancin: Oritavancin IV (Intravenous) Formulation, Oritavancin Powder for Injection

4) By Other Drugs: Teicoplanin, Glycopeptide and Lipoglycopeptide Antibiotics

What Industry Trends Are Transforming The Glycopeptide Antibiotics Market?

Leading firms within the glycopeptide antibiotics market are prioritizing the creation of cutting-edge offerings, including innovative glycopeptide scaffolds, to secure a competitive edge. These new glycopeptide scaffolds are structurally unique antibiotic foundations, obtained through sophisticated biosynthetic methods or natural-product discovery processes. For example, in May 2025, a Chinese-European research consortium, recognized for its cross-continental expertise based in China, unveiled Saarvienin A. This recently identified glycopeptide incorporates a halogenated peptide core, a distinctive ureido linkage, and five different sugar or aminosugar components. Saarvienin A diverges from other glycopeptides by not binding to the conventional cell-wall target, suggesting a potentially new mechanism of action. Furthermore, it demonstrates strong in vitro efficacy against resistant Gram-positive pathogens like MRSA and vancomycin-resistant Enterococcus. While this breakthrough signifies substantial progress in combating antibiotic resistance, it encounters obstacles such as clinical application, enhancing safety, and expanding production.

Who Are The Primary Competitors In The Global Glycopeptide Antibiotics Market?

Major companies operating in the glycopeptide antibiotics market are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Glycopeptide Antibiotics Market?

North America was the largest region in the glycopeptide antibiotics market in 2025. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Glycopeptide Antibiotics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9444&type=smp

Browse Through More Reports Similar to the Global Glycopeptide Antibiotics Market 2026, By The Business Research Company

Glycopeptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Peptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795